Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Akerna Corp. KERNW NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Healthcare Information Services • US • USD

SharesGrow Score
31/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Akerna Corp. (KERNW) is a Medical - Healthcare Information Services company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 29/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $185,164, -27.5%/yr average growth. Net income is $153,171 (loss), growing at +29.4%/yr. Net profit margin is -82.7% (negative). Gross margin is 50.3% (-10.4 pp trend).

Balance sheet: total debt is $188M against $666M equity (Debt-to-Equity (D/E) ratio 0.28, conservative). Current ratio is 0.08 (tight liquidity). Debt-to-assets is 15.1%. Total assets: $1.2B.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 35/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

KERNW SharesGrow Score Overview

38/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 35/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — KERNW

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
KERNW: -27.5%/yr revenue is, +29.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet KERNW: Debt-to-Equity (D/E) ratio 0.28 (conservative), Current ratio is 0.08 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
35/100
KERNW: Gross margin is 50.3% (-10.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 35/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
KERNW: Net profit margin is -82.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range7.0E-4-0.004
Volume205.62K
Market Cap$162.32K
Beta (1Y)2.79
Share Statistics
EPS (TTM)0.00
Shares Outstanding$899.35M
IPO Date2018-02-27
Employees2
CEOSai Kit Chang
Financial Highlights & Ratios
Revenue (TTM)$185.16K
Gross Profit$93.16K
EBITDA$-113.05K
Net Income$-153.17K
Operating Income$-227.99K
Total Cash$3.82M
Total Debt$188.4M
Net Debt$184.57M
Total Assets$1.25B
Price / Earnings (P/E)-3.5
Price / Sales (P/S)0.88
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS00973W1100

Price Chart

Track all markets on TradingView
KERNW
Akerna Corp. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Healthcare Information Services

People Also View

IMACW
IMACW
IMAC Holdings, Inc.
$0.01
+10.09%
 THWWW
THWWW
Target Hospitality Corp.
$0.00
+0.00%
 GMBLW
GMBLW
Esports Entertainment Group, Inc.
$0.04
+2,368.75%
 ARTLW
ARTLW
Artelo Biosciences, Inc.
$0.01
+0.00%
 ADILW
ADILW
Adial Pharmaceuticals, Inc. WT EXP 073123
$0.00
-57.14%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message